Abbott launches Oncodetect molecular residual disease test tracking up to 5,000 patient-specific variants

Abbott announced the commercial launch of its Oncodetect molecular residual disease (MRD) test, a next-generation diagnostic that uses whole-genome sequencing and proprietary MAESTRO technology to track up to 5,000 patient-specific variants, with a limit of detection below one part per million. The company presented related data in a poster at the ESMO 2026 congress in Madrid.

Detected & updated continuously · Source: Nebula